GerdCare Medical

Company Overview

Snapshot

Founded in September 2017 by Shimon Eckhouse, Moti Esh, and Giora Arbel, GerdCare Medical operates with 1–10 employees. The company has secured funding across two rounds, with an investment in April 2025 from Alon MedTech Ventures.

Business overview

GerdCare Medical is pioneering a non-invasive, drug-free technology to treat Gastroesophageal Reflux Disease (GERD), addressing a critical unmet clinical need for over one billion affected individuals globally. The company's core solution includes a smart wearable device for targeted electrical stimulation, a proprietary mobile app for personalized treatment optimization, and a clinician dashboard for remote patient monitoring. GerdCare Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving patients and providers in the United States, Europe, and globally.

Company Intelligence Q&A

What is GerdCare Medical's primary focus?

GerdCare Medical is focused on developing the first-ever non-invasive and drug-free technology to treat Gastroesophageal Reflux Disease (GERD), targeting the root cause rather than just symptoms.

When was GerdCare Medical founded?

GerdCare Medical was founded in September 2017.

Who are the founders of GerdCare Medical?

GerdCare Medical was founded by Shimon Eckhouse, Moti Esh, and Giora Arbel.

What is the status of GerdCare Medical's clinical trials?

GerdCare Medical has conducted proof-of-concept and pilot studies demonstrating rapid symptom relief and an excellent safety profile, and a pivotal, FDA-approved clinical trial is currently enrolling patients.